Show simple item record

dc.contributor.authorKoch, C
dc.contributor.authorKuske, A
dc.contributor.authorJoosse, SA
dc.contributor.authorYigit, G
dc.contributor.authorSflomos, G
dc.contributor.authorThaler, S
dc.contributor.authorSmit, DJ
dc.contributor.authorWerner, S
dc.contributor.authorBorgmann, K
dc.contributor.authorGärtner, S
dc.contributor.authorMossahebi Mohammadi, P
dc.contributor.authorBattista, L
dc.contributor.authorCayrefourcq, L
dc.contributor.authorAltmüller, J
dc.contributor.authorSalinas-Riester, G
dc.contributor.authorRaithatha, K
dc.contributor.authorZibat, A
dc.contributor.authorGoy, Y
dc.contributor.authorOtt, L
dc.contributor.authorBartkowiak, K
dc.contributor.authorTan, TZ
dc.contributor.authorZhou, Q
dc.contributor.authorSpeicher, MR
dc.contributor.authorMüller, V
dc.contributor.authorGorges, TM
dc.contributor.authorJücker, M
dc.contributor.authorThiery, J-P
dc.contributor.authorBrisken, C
dc.contributor.authorRiethdorf, S
dc.contributor.authorAlix-Panabières, C
dc.contributor.authorPantel, K
dc.date.accessioned2020-09-30T09:42:10Z
dc.date.issued2020-09
dc.identifier.citationEMBO molecular medicine, 2020, 12 (9), pp. e11908 - ?
dc.identifier.issn1757-4676
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4083
dc.identifier.eissn1757-4684
dc.identifier.doi10.15252/emmm.201911908
dc.description.abstractFunctional studies giving insight into the biology of circulating tumor cells (CTCs) remain scarce due to the low frequency of CTCs and lack of appropriate models. Here, we describe the characterization of a novel CTC-derived breast cancer cell line, designated CTC-ITB-01, established from a patient with metastatic estrogen receptor-positive (ER+ ) breast cancer, resistant to endocrine therapy. CTC-ITB-01 remained ER+ in culture, and copy number alteration (CNA) profiling showed high concordance between CTC-ITB-01 and CTCs originally present in the patient with cancer at the time point of blood draw. RNA-sequencing data indicate that CTC-ITB-01 has a predominantly epithelial expression signature. Primary tumor and metastasis formation in an intraductal PDX mouse model mirrored the clinical progression of ER+ breast cancer. Downstream ER signaling was constitutively active in CTC-ITB-01 independent of ligand availability, and the CDK4/6 inhibitor Palbociclib strongly inhibited CTC-ITB-01 growth. Thus, we established a functional model that opens a new avenue to study CTC biology.
dc.formatPrint-Electronic
dc.format.extente11908 - ?
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleCharacterization of circulating breast cancer cells with tumorigenic and metastatic capacity.
dc.typeJournal Article
dcterms.dateAccepted2020-06-17
rioxxterms.versionofrecord10.15252/emmm.201911908
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2020-09
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfEMBO molecular medicine
pubs.issue9
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Endocrine control mechanisms
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Endocrine control mechanisms
pubs.publication-statusPublished
pubs.volume12
pubs.embargo.termsNo embargo
icr.researchteamEndocrine control mechanismsen_US
dc.contributor.icrauthorBrisken, Cathrinen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0